Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Blockhead11-14

Shares of Avidity Biosciences (RNA) surged to a record high Wednesday after the company showed its hand in the cardiovascular space — a first for the company's RNA platform. ↑ X How To Buy ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483831192?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg","is_english":true,"pubTime":"2024-11-14 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483831192","market":"us","top_or_hot":-1,"title":"Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News","media":"Blockhead","content":"<div>\n<p>Shares of Avidity Biosciences (RNA) surged to a record high Wednesday after the company showed its hand in the cardiovascular space — a first for the company's RNA platform.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy ...</p>\n\n<a href=\"https://www.investors.com/news/technology/avidity-biosciences-stock-cardiovascular-disease-bristol-myers-squibb/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/avidity-biosciences-stock-cardiovascular-disease-bristol-myers-squibb/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Avidity Biosciences (RNA) surged to a record high Wednesday after the company showed its hand in the cardiovascular space — a first for the company's RNA platform.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy ...</p>\n\n<a href=\"https://www.investors.com/news/technology/avidity-biosciences-stock-cardiovascular-disease-bristol-myers-squibb/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/avidity-biosciences-stock-cardiovascular-disease-bristol-myers-squibb/","article_id":"2483831192","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483831192","pubTimestamp":1731515081,"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0237698245.USD":"富达环球地产基金A","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4139":"生物科技","BK4007":"制药","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","BK4559":"巴菲特持仓","BMY":"施贵宝","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4588":"碎股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","RNA":"Avidity Biosciences, Inc.","BK4581":"高盛持仓","BK4505":"高瓴资本持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC"},"translate_title":"Avidity Bio今年股价飙升416%——这还是在今天“改变游戏规则”的新闻发布之前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1,"BMY":1},"content_text":"Shares of Avidity Biosciences (RNA) surged to a record high Wednesday after the company showed its hand in the cardiovascular space — a first for the company's RNA platform.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: Do You Know Your Stock's Personality Type?\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: Do You Know Your Stock's Personality Type?\n\n\n\n\nThis has the potential to be \"game-changing,\" Chief Executive Sarah Boyce told Investor's Business Daily in a recent interview. Under its partnership with Bristol Myers Squibb (BMY), Avidity plans to test out treatments for two rare diseases, PLN cardiomyopathy and PRKAG2 syndrome.\nBoth diseases are driven by genetic causes. In laboratory testing, Avidity's drugs lowered the amount of disease-causing protein in the heart by about 80%.\nGenerally, cardiologists don't study the genetics of their patients.\n\"We are proud to be the first company to successfully deliver siRNA (small interfering RNA) directly to skeletal muscle and now, we have demonstrated that we can deliver siRNA against targets in the heart in preclinical studies,\" Boyce said in a written statement.\nIn early action, Avidity Biosciences stock rocketed more than 15% to 54.05. Shares trounced their previous record high at 50.76.\nAvidity Biosciences Enters Cardio Space\nThere are no approved treatments for PLN cardiomyopathy or PRKAG2 syndrome. They are caused by mutations in the PLN and PRKAG2 genes, respectively. The former causes dilation of the heart chambers, sudden cardiac death and heart failure. The latter leads to thickening of the heart muscle, irregular heartbeats and other problems.\nSo far, Avidity Biosciences has tested its treatments in nonhuman primates.\n\"However, it is important to note the small sample of NHP data presented, and, as yet, no data presented from a disease model,\" Chardan analyst Keay Nakae said in a report. \"A major feature of both diseases is the physiological changes that occur in the heart, and it is yet to be determined if either of these therapies will lead to a functional reversal of those changes.\"\nStill, the move is unique for the RNA space. These drugs try to silence the genes responsible for making disease-causing proteins. Biotech companies first focused on delivering RNA-targeting drugs to the liver. Now, they're expanding into other tissue types.\nAvidity Biosciences ultimately plans to test 10 cardiovascular targets with partner Bristol.\n\"We're looking to lead the space,\" Boyce told IBD.\nTop 1% Biotech Stock\nAvidity Biosciences stock had soared more than 416% this year, as of Tuesday's close.\nShares have a perfect IBD Digital Relative Strength Rating of 99. This puts them in the top 1% of all stocks in terms of 12-month performance.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nAmgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot\nTop Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal\nFollow Premarket And After-The-Open Action With IBD Experts\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks\nLearn How To Time The Market With IBD's ETF Market Strategy","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483831192"}